Sanofi-Aventis U.S. LLC

Throughout June close to 50 communities will be gathering across Canada to raise funds for type 1 diabetes researchTORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The JDRF Walk to Cure Diabetes is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research. A fun-filled family and community celebration, the Walk has raised more than $140 million to date making it one of the longest running and most successful fundraising events in the country. Throughout June, close to 50 Walk events will be held across the country. The collective fundraising goal is $3.7 million that will help support JDRF’s mission to cure T1D. 2024 marks the 50th anniversary of JDRF Canada, and this event pays tribute to the organization’s grassroots foundations. JDRF is excited to bring together our T1D community to recognize 50 years of progress, momentum and breakthroughs in T1D research. T1D is an autoimmune disease that affects close to 300,000 Canadians. For over 100 years, the only available treatment has been insulin, and even with careful management there is the risk of diabetes-related complications like kidney failure, blindness, amputation and even death. Canada has one of the fastest-growing rates of diagnosis in the world, and we don’t know why. There is currently no medication or therapy that can improve disease outcomes and no cure. Continued investment in ground-breaking research, such as stem cell-based treatments that can produce insulin in those living with the disease, is crucial for improved treatments and cures. Quotes: “The Walk is truly a special event and feels even more meaningful as we mark 50 years of JDRF in Canada,” says Jessica Diniz, President and CEO of JDRF Canada. “This organization began with dedicated parents looking drive T1D research, and we honour that legacy every year at the Walk, bringing together the T1D community for this singular goal. Funds raised from the JDRF Walk to Cure Diabetes will help improve lives of Canadians living with T1D by accelerating life-changing breakthroughs to treat, prevent and cure T1D.” The Walk’s newest sponsor, Sanofi, has come onboard as National Awareness Partner. "Building on our strong legacy in diabetes care, Sanofi Canada's commitment to helping Canadians living with diabetes goes beyond medicine,” says Ahmed Moussa, General Manager of General Medicines at Sanofi Canada. “We're proud to sponsor the JDRF Walk to Cure Diabetes to provide an opportunity for people across Canada to come together and raise awareness about type 1 diabetes, ensuring that education and support are available to all." Abbott’s Diabetes Care division has returned as the Walk’s National Premier Partner. “At Abbott, we deeply value our long-standing commitment to supporting JDRF, the community and people living with diabetes,” says Luz Herrera, General Manager, Abbott’s Diabetes Care division in Canada. “As part of this commitment, Abbott is honoured to continue our partnership with JDRF in supporting families and accelerating research and innovation in treating type 1 diabetes.” Learn more about the 2024 JDRF Walk to Cure Diabetes and help us move T1D research forward faster: jdrfwalk.ca About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.ca. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews. About Sanofi Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. In Canada, Sanofi employs over 2,000 people and invests annually of 20% of its revenue in biopharma research, representing CAD $1.2 billion in R&D over the last decade, creating jobs, business, and opportunities throughout the country. From our state-of-the-art Campus in Toronto, we research, develop, manufacture, commercialize and distribute Sanofi products to people in this country and around the world. In 2024, we are celebrating 110 years of heritage. What started as a small laboratory in May of 1914, has evolved to become the largest biomanufacturing facility in Canada. Today, we remain committed to discovering, developing, and delivering innovative medicine and vaccine solutions for people that need them. For more information: Ruth KapelusNational Content & Media Relations Manager, JDRF CanadaT. 647.789.2322E. rkapelus@jdrf.ca

LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. “On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth,” said President and Chief Executive Officer Jasbir Seehra, Ph.D. “Jean-Jacques is a deeply accomplished executive who brings a wealth of experience in the biotechnology and pharmaceutical industries, spanning executive leadership, governance, strategic planning, product development and commercialization. This broad expertise will be an important asset to the Board and the Company as we continue to progress our existing pipeline of differentiated product candidates.” Mr. Bienaimé served as the Chief Executive Officer of BioMarin Pharmaceutical Inc. from May 2005, and as the Chairman from June 2015, until his retirement from BioMarin in December 2023. From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Prior to Genencor, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and Chief Executive Officer in 1999. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to 1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the board of directors of Incyte Corporation and Immunome, Inc., as well as serving on the board of directors of a private biotechnology company. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis. Keros’ second product candidate, KER-012 (cibotercept), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. Investor Contact: Justin Frantz jfrantz@kerostx.com 617-221-6042

ALTON, Ill. and NEW YORK, April 2, 2024 /PRNewswire/ -- Simmons Hanly Conroy, one of the nation's leading mass tort litigation firms dedicated to holding corporations responsible for wrongdoing, today announced that attorney and Named Partner Jayne Conroy has been appointed to the Plaintiffs' Executive Committee (PEC) for the Insulin Price Fixing Multidistrict Litigation (MDL) in the United States District Court of the District Of New Jersey. District Judge Brian R. Martinotti will oversee the three main cases of the litigation. The litigation involves plaintiffs who say three of the largest pharmaceutical companies in the world, Eli Lilly and Co., Novo Nordisk Inc., and Sanofi-Aventis U.S. LLC, artificially inflated the prices of lifesaving insulin in order to profit at the expense of the health and livelihood of individuals with diabetes or prediabetes in communities across the United States. "The drug and pharmacy benefit manufacturers involved in this case have upheld and perpetuated dangerous and deceptive drug pricing practices that have put many lives at risk across the nation," said Jayne Conroy, Named Partner at Simmons Hanly Conroy. "I am honored to be selected to the Plaintiffs' Executive Committee of such a pivotal suit for insulin users and their communities. This suit seeks to secure accountability against these corporations, ensure the wellbeing of affected individuals in the near and long term, and bring an end to the predatory pricing of insulin." Conroy oversees Simmons Hanly Conroy's Complex Litigation Department. Under her leadership, Simmons Hanly Conroy has become one of the country's largest plaintiff law firms dedicated to helping those injured by corporate wrongdoing. Conroy has helped secure billions of dollars in verdicts and settlements for thousands of individuals, families, and communities across the country. With more than three decades of legal experience, she focuses her practice on helping plaintiffs exclusively in mass torts, class actions, product liability, pharmaceutical and sexual abuse litigation. Conroy serves or has served on dozens of court-appointed leadership committees in complex legal actions of national scope. Conroy also serves as co-lead of the National Prescription Opiate Multidistrict Litigation in the Northern District of Ohio, and as co-lead and interim class counsel representing plaintiffs in the case against Norfolk Southern, the company responsible for the Feb. 3, 2023 East Palestine, Ohio train derailment. Additionally, she has served on the Plaintiffs' Executive Committee of the Camp Lejeune Contaminated Water Litigation. Since its inception, Simmons Hanly Conroy has successfully helped thousands of clients across the country harmed by corporate wrongdoing. About Simmons Hanly Conroy, LLP Simmons Hanly Conroy, with nearly 250 employees, including more than 100 attorneys practicing nationwide, is one of the country's largest plaintiff law firms dedicated to holding corporations responsible for wrongdoing. Primary areas of litigation include mesothelioma and asbestos, pharmaceutical and medical device injuries, consumer protection class actions, environmental injuries and protection, and complex personal injury. The firm's attorneys have been appointed to leadership in numerous national multidistrict litigations, including prescription opioids, Vioxx, Toyota unintended acceleration, BP Deepwater Horizon Oil Spill, DePuy Pinnacle and the Volkswagen emission scandal. Since 1999, the firm has secured $10.2 billion in verdicts and settlements for thousands of clients nationwide and is a major supporter of asbestos-related cancer research. Offices are located in Alton, Ill.; Los Angeles; New York City; San Francisco; and St. Louis. Read more at . Media Contact: [email protected] SOURCE Simmons Hanly Conroy